Diabetes Mellitus and the Risk and Outcomes of Clostridioides Difficile Infection: A Systematic Review.|https://dx.doi.org/10.2147/IDR.S562597
Rectal Fidaxomicin as Salvage Therapy in Fulminant Clostridioides difficile Infection After Total Colectomy: A Case Report.|https://dx.doi.org/10.36518/2689-0216.1843
Prevention of recurrent Clostridioides difficile infection by fecal microbiota, live-jslm (REBYOTA(Â®)) administered via colonoscopy: 6-month data from the single-arm phase IIIb CDI-SCOPE trial.|https://dx.doi.org/10.1177/17562848251396744
Clinical characteristics and risk factors for Clostridioides difficile infection in the hematopoietic cell transplantation population.|https://dx.doi.org/10.1017/ice.2025.10330
Design and application of synthetic human gut microbial communities.|https://dx.doi.org/10.1080/19490976.2025.2575923
Diagnosis and Management of C. difficile.|https://dx.doi.org/10.14309/ajg.0000000000003844
A Tale of Two Infections: A Rare Synchronous Infection of Herpes Simplex Virus Oesophagitis and Clostridium difficile in an Immunocompetent Host.|https://dx.doi.org/10.7759/cureus.94660
Integrated analysis of the safety of fecal microbiota, live-jslm in adults with recurrent Clostridioides difficile infection from five prospective clinical trials: an update.|https://dx.doi.org/10.1177/17562848251395566
FMT promotes type 2 mucosal immune responses with colonic epithelium proliferation in recurrent CDI patients.|https://dx.doi.org/10.1172/jci.insight.195678
Correction: Budget Impact Analysis of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) for Recurrent Clostridioides difficile Infection in the United States.|https://dx.doi.org/10.1007/s40121-025-01266-4
The sex hormone-gut microbiome axis: mechanistic drivers of sex-disparate bacterial infection outcomes and precision clinical interventions.|https://dx.doi.org/10.1128/cmr.00236-25
Interventions to optimize duration of antibiotic therapy and encourage oral transition for uncomplicated gram-negative blood stream infections across a health system.|https://dx.doi.org/10.1017/ice.2025.10359
Clostridioides difficile: A suspected pro-carcinogenic bacterium for gastrointestinal tumors.|https://dx.doi.org/10.1097/CM9.0000000000003834
Increasing patient access to faecal microbiota transplantation with remote delivery: a cost analysis of outpatient versus home-based treatment.|https://dx.doi.org/10.1186/s13561-025-00706-8
Successful Fecal Microbiota Transplants in Post-antibiotic Treated Recurrent Clostridioides difficile Patients Induce Acylcarnitine and Sphingolipid Lipidomic Shifts.|https://dx.doi.org/10.21203/rs.3.rs-7888346/v1
Recurrent Clostridium difficile Infections in a Patient With Ulcerative Colitis: A Case Report.|https://dx.doi.org/10.7759/cureus.95130
Pharmacological reduction of neutrophil infiltration reduces Clostridioides difficile infection severity.|https://dx.doi.org/10.1101/2025.10.30.685526
Biliverdin targeting TcdB-DRBD inhibits Clostridioides difficile virulence and restores gut microbiota in Mongolian gerbils (Meriones unguiculatus).|https://dx.doi.org/10.1038/s42003-025-09059-8
Case Report: Idiopathic myointimal hyperplasia of mesenteric veins mimicking inflammatory bowel disease: a case report with literature review.|https://dx.doi.org/10.3389/fmed.2025.1674469
Faecal microbiota transplantation for primary Clostridioides difficile infection.|https://dx.doi.org/10.4045/tidsskr.25.0276
Untargeted Metabolomics Identifies Faecal Filtrate-Derived Metabolites That Disrupt Clostridioides difficile Metabolism and Confer Gut Barrier Cytoprotection.|https://dx.doi.org/10.3390/ijms262211221
Clostridioides difficile Infection in Special Populations: Focus on Inflammatory Bowel Disease-A Narrative Review from Pathogenesis to Management.|https://dx.doi.org/10.3390/biomedicines13112702
